Hero Image

Obesity is a function of biology.

ERX Pharmaceuticals Inc. is developing first-in-class leptin sensitizers for the treatment of obesity and related diseases based on a new understanding of the science of obesity.
Learn More
obese man smiling and talking on phone

Obesity

ERX is developing first-in-class leptin sensitizers to address unmet needs in the treatment of obesity.

Learn More
Metabolic Diseases

Metabolic Diseases

Insensitivity to leptin signaling contributes to a range of metabolic diseases, which may be addressable by leptin sensitizers.

Learn More
Hypothalamus Extended
37 catens outline copyCreated with Sketch.

Research + Development

Targeting Leptin Resistance

Leptin signaling plays a critical role in the body’s regulation of food intake and energy expenditure. ERX believes that improving leptin sensitivity can yield significant clinical benefits across a range of metabolic diseases, including obesity.
Learn more
dna-outline-94Created with Sketch.

Pipeline

Drug Discovery and Development

ERX has several drug candidates in the pipeline, from ERX-1000 currently in the clinic, to additional compounds in preclinical or discovery stages.
View Pipeline